Dubbed TAK-861-2001, the trial enrolled 112 subjects with NT1, a chronic, rare neurological central hypersomnolence disorder. The trial demonstrated a statistically significant and clinically ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...